Capital Advisory Group Advisory Services’s GSK GSK Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-356	Closed	-$19K	–	318
2022 Q1	$19K	Buy	+356	New	+$19.3K	0.01%	304
2021 Q4	–	Sell	-532	Closed	-$25K	–	292
2021 Q3	$25K	Hold	532	–	–	0.01%	303
2021 Q2	$26K	Hold	532	–	–	0.01%	305
2021 Q1	$24K	Hold	532	–	–	0.01%	299
2020 Q4	$24K	Buy	532 +59	+12%	+$2.71K	0.01%	297
2020 Q3	$22K	Hold	473	–	–	0.01%	254
2020 Q2	$24K	Hold	473	–	–	0.01%	237
2020 Q1	$23K	Buy	+473	New	+$25.2K	0.03%	149
2019 Q4	–	Sell	-605	Closed	-$32K	–	288
2019 Q3	$32K	Hold	605	–	–	0.02%	173
2019 Q2	$31K	Hold	605	–	–	0.02%	183
2019 Q1	$31K	Hold	605	–	–	0.02%	176
2018 Q4	$29K	Hold	605	–	–	0.02%	172
2018 Q3	$31K	Buy	605 +88	+17%	+$4.47K	0.02%	164
2018 Q2	$26K	Sell	517 -815	-61%	-$41K	0.02%	166
2018 Q1	$65K	Buy	+1,332	New	+$62K	0.05%	121

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Capital Advisory Group Advisory Services's GSK Position: Q2 2022 in Review

Capital Advisory Group Advisory Services sold out of GSK (GSK) in Q2 2022, closing a stake of 356 shares — an estimated $19K sold.

Capital Advisory Group Advisory Services first reported a position in GSK in Q1 2018 and held it in 15 quarters. The position peaked at $65K in Q1 2018. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

Capital Advisory Group Advisory Services reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
Capital Advisory Group Advisory Services sold 356 GSK shares in Q2 2022, an estimated $19K.
Capital Advisory Group Advisory Services first reported a position in GSK in Q1 2018 and held it in 15 quarters.
Capital Advisory Group Advisory Services's GSK position peaked at $65K in Q1 2018.
900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Capital Advisory Group Advisory Services's 13F filing for Q2 2022, filed 12 Aug 2022.